NCT02919969View on ClinicalTrials.gov

Pembrolizumab in Metastatic Anal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 11, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

March 31, 2023

Conditions
Anal Cancer
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.

Trial Locations (4)

98109

Seattle Cancer Care Alliance, Seattle

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT02919969 - Pembrolizumab in Metastatic Anal Cancer | Biotech Hunter | Biotech Hunter